224
Views
0
CrossRef citations to date
0
Altmetric
Case reports

A Rare Case of Apixaban-Induced Subdural Hematoma in Elderly Heart Failure Patient

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, , , , & ORCID Icon show all
Pages 623-626 | Received 28 Jul 2023, Accepted 22 Sep 2023, Published online: 28 Sep 2023

References

  • Crowther M, Cuker A. How can we reverse bleeding in patients on direct oral anticoagulants? Kardiol Pol. 2019;77(1):3–11. doi:10.5603/KP.a2018.0197
  • Deng Y, Tong Y, Deng Y, Zou L, Li S, Chen H. Non–vitamin K antagonist Oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta‐analysis. J Am Heart Assoc. 2019;8(14):e012540. doi:10.1161/JAHA.119.012540
  • Msheik A, Fares Y, Mohanna M, et al. Middle meningeal artery embolisation: the review of a new treatment for chronic subdural hematomas. Surg Neurol Int. 2023;14:14. doi:10.25259/SNI_1112_2022
  • Snopko P, Kolarovszki B, Opsenak R, Hanko M, Benco M. Chronic calcified subdural hematoma-case report of a rare diagnosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020;164(2):209–212. doi:10.5507/bp.2019.041
  • Alayad E, Khairy S, Aloraidi A. Apixaban-induced subdural bleeding: case presentation and literature review. Case Rep. 2018;2018:bcr–2018.
  • Wendte J, Voss G, VanOverschelde B. Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury. Am J Health Syst Pharm. 2016;73(8):563–567. doi:10.2146/ajhp150360
  • Bloom BJ, Filion KB, Atallah R, Eisenberg MJ. Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. Am J Cardiol. 2014;113(6):1066–1074. doi:10.1016/j.amjcard.2013.11.049
  • Abu Hishmeh M, Srivastava P, Lougheide Q, Srinivasan M, Murthy S. Massive spontaneous hemothorax as a complication of apixaban treatment. Case Rep Pulmonol. 2018;2018:1–4. doi:10.1155/2018/8735036
  • Rinehart DR, Lockhart NR, Hamilton LA, Langdon JR, Rowe AS. Management of apixaban-associated subdural hematoma: a case report on the use of factor eight inhibitor bypassing activity. Crit Care Med. 2015;43(6):e203–e207. doi:10.1097/CCM.0000000000000909
  • Colell A, Arboix A, Caiazzo F, Grivé E. Iatrogenic spinal subdural hematoma due to apixaban: a case report and review of the literature. Case Rep Hematol. 2018;2018:1–5. doi:10.1155/2018/4507638
  • Ardebol J, Cahueque M, Lopez W, Azmitia E. Spontaneous thoracic spinal subdural hematoma associated with apixaban therapy. J Surg Case Rep. 2019;2019(4):rjz115. doi:10.1093/jscr/rjz115
  • Beynon C, Potzy A, Unterberg AW, Sakowitz OW. Emergency neurosurgical care in patients treated with apixaban: report of 2 cases. Am J Emerg Med. 2014;33(6):858–e5.
  • Lee MT, Park KY, Kim MS, You SH, Kang YJ, Jung SY. Concomitant use of NSAIDs or SSRIs with NOACs requires monitoring for bleeding. Yonsei Med J. 2020;61(9):741. doi:10.3349/ymj.2020.61.9.741
  • Kessler CM, Goldstein JN. A new strategy for uncontrollable bleeding after treatment with rivaroxaban or apixaban. Clin Adv Hematol Oncol. 2019;17(suppl 15):1–20.
  • Haas S, Camm AJ, Bassand JP, et al. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Am Heart J. 2019;213:35–46. doi:10.1016/j.ahj.2019.03.013
  • Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors–clinical utility of andexanet alfa. J Blood Med. 2017;8:141–149. doi:10.2147/JBM.S121550